These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38364230)

  • 1. A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer.
    Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
    Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A photoactivatable upconverting nanodevice boosts the lysosomal escape of PROTAC degraders for enhanced combination therapy.
    Zhan J; Li X; Mu Y; Yao H; Zhu JJ; Zhang J
    Biomater Sci; 2024 Jul; 12(14):3686-3699. PubMed ID: 38873991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
    Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
    Acta Pharmacol Sin; 2024 Aug; 45(8):1740-1751. PubMed ID: 38609561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy.
    Wang W; Zhu C; Zhang B; Feng Y; Zhang Y; Li J
    J Am Chem Soc; 2023 Aug; 145(30):16642-16649. PubMed ID: 37477624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy.
    Gao J; Jiang X; Lei S; Cheng W; Lai Y; Li M; Yang L; Liu P; Chen XH; Huang M; Yu H; Xu H; Xu Z
    Nat Commun; 2024 Aug; 15(1):6608. PubMed ID: 39098906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both
    Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
    J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
    He S; Gao F; Ma J; Ma H; Dong G; Sheng C
    Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
    He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
    J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.
    Zhang HT; Peng R; Chen S; Shen A; Zhao L; Tang W; Wang XH; Li ZY; Zha ZG; Yi M; Zhang L
    Adv Sci (Weinh); 2022 Oct; 9(29):e2202039. PubMed ID: 35988145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
    Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
    ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
    Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
    Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BRD4 with PROTAC degrader ameliorates LPS-induced acute lung injury by inhibiting M1 alveolar macrophage polarization.
    Li D; Deng Y; Wen G; Wang L; Shi X; Chen S; Chen R
    Int Immunopharmacol; 2024 May; 132():111991. PubMed ID: 38581996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
    Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
    Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A BRD4-Targeting Photothermal Agent for Controlled Protein Degradation.
    Shi M; Li Y; Pan W; Fu Z; Wang K; Liu X; Li N; Tang B
    Angew Chem Int Ed Engl; 2024 Jul; 63(29):e202403258. PubMed ID: 38721770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.